The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded $683,500 to Luminex (NASDAQ:LMNX) to support the enhancement of its xMAP SARS-CoV-2 Multi-Antigen IgG Assay which detects antibodies to three antigens of the coronavirus.
The company intends to submit the updated test to the FDA for emergency use during the pandemic.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.